EDE015-b Molecular Imaging Case of the Day Education Exhibits Location: NA Participants Moderator Umar Mahmood MD, PhD Research Grant, Sabik Medical Inc Rahul Anil Sheth MD : Nothing to Disclose Manuela Cristina Matesan MD, PhD : Nothing to Disclose David H. Lewis MD : Research Consulant, Eli Lilly and Company Satoshi Minoshima MD, PhD : License agreement, General Electric Company Research Grant, Koninklijke Philips Electronics NV Research Grant, Hitachi, Ltd Research Consultant, Hamamatsu Photonics KK Grant, Nihon Medi-Physics Co, Ltd Research Grant, Astellas Group Research Grant, Seattle Genetics, Inc Baris Turkbey MD : Nothing to Disclose Peter L. Choyke MD : Researcher, Koninklijke Philips NV Researcher, General Electric Company Researcher, Siemens AG Researcher, iCAD, Inc Researcher, Aspyrian Therapeutics, Inc Researcher, ImaginAb, Inc Researcher, Aura Daniel Pryma MD : Research Grant, Siemens AG Research Grant, Molecular Insight Pharmaceuticals, Inc Speaker, IBA Molecular Advisory Board, Bayer AG Michael David Farwell MD, MA : Nothing to Disclose David A. Mankoff MD, PhD : Speaker, Koninklijke Philips NV Speaker, Siemens AG Speaker, General Electric Company Yusuf Menda MD : Research Grant, Advanced Accelerator Applications John Sunderland PhD : Research Grant, Siemens AG Ravi A. Madan MD : Nothing to Disclose MIE001-b Oncogenic Osteomalacia, What Does It Look Like? From SPECT to Plain Films with Pathologic Correlation Education Exhibits Location: NA Participants Jesus Alejandro Gabutti MD (Presenter): Nothing to Disclose Ailan Hitandhui Barrientos-Priego MD : Nothing to Disclose Joaquin Nunez Gomez MD : Nothing to Disclose Daniela Canaviri MD : Nothing to Disclose Fritz Hofmann MD : Nothing to Disclose Jorge Vazquez-Lamadrid MD : Nothing to Disclose Fernando Cano MD : Nothing to Disclose TEACHING POINTS To explain the pathophysiology con oncogenic osteomalacia. To explain the importance of molecular imaging, with special emphasis in SPECT-CT for the correct diagnosis. To show and explain the main imaging findings in MRI, US, CT and plain films of mesenchymal tumor, systemic manifestations, complications and consequences of a delay diagnosis. To emphasize the importance of the radiologist in the approach of a patient of suspected oncogenic osteomalacia. TABLE OF CONTENTS/OUTLINE Introduction: epidemiology and pathogenesis. Clinical and laboratory findings. Imaging work-up, indications and algorithm. SPECT and SPECT-CT findings, radiotracers and technique. Other molecular imaging methods. Review of cases with radiologic-pathologic correlation: MRI and ultrasound appearance of the mesenchymal tumor. CT and plain films of the systemic manifestations and complications. Summary of the teaching points and conclusion. MIE002-b Simultaneous Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI): Clinical Advances and Implications in Neuroimaging of Epilepsy Education Exhibits Location: NA Participants Emmanuel C. Obusez MD (Presenter): Nothing to Disclose Shetal N. Shah MD : Nothing to Disclose Bandar Osaid Safar MD : Nothing to Disclose Unni K. Udayasankar MD, FRCR : Nothing to Disclose Guiyun Wu MD : Nothing to Disclose Stephen Edward Jones MD, PhD : Nothing to Disclose TEACHING POINTS 1. Emphasize the clinical significance of simultaneous PET/MRI in the improving the detection of epilepsy foci. 2. Illustrate with simultaneous fused-FDG-PET/MRI findings of epileptic foci. TABLE OF CONTENTS/OUTLINE 1. Briefly review the role of MRI in epilepsy a. Discuss current MRI imaging findings and limitations in the evaluation of epilepsy foci. Limited to focal cortical dysplasia, meso temporal sclerosis, polymicrogyria and heterotopia. 2. Describe current technical advances in PET/MRI and its use in neuroimaging. 3. Discuss the clinical utility of fused-FDG-PET/MRI for evaluation of epilepsy foci and advantages over structural MRI. Fused-PET/MRI is a modality that offers superior diagnostic advantages. Patients with medically refractory epilepsy may be candidates for surgery. This cohort of patients may have a positive surgical outcome with the identification of epileptic foci on MRI. However, some patients show indeterminate or no evidence of structural abnormality on MRI. In these subset of patients, fused-FDG-PET/MRI is increasing being used as a tool to enhance pre-surgical identification of epileptic foci. Learn the clinical utility of fused-FDG-PET/MRI and its advantages - such as new regions of hypometabolic epileptic foci not seen on MRI and ability to delineate anatomic boundaries of hypometabolism not identified on PET. MIE003-b Utility of 18F-FDG PET/CT and 11C-Acetate PET/CT in Restaging of Prostate Cancer: A Review of the Literature Education Exhibits Location: NA Participants Erika Morrongo Bastida MD (Presenter): Nothing to Disclose Juan Pablo Chavez Torres MD : Nothing to Disclose Ailan Hitandhui Barrientos-Priego MD : Nothing to Disclose Jose Rafael Garcia Ortiz MD : Nothing to Disclose Maria Mayela Leon Sanchez : Nothing to Disclose Irma Soldevilla-Gallardo : Nothing to Disclose TEACHING POINTS 1.To review differences in the metabolic pathway and biodistribution of each radiopharmaceutical 2.To know the use that has been given in the literature to 18F FDG PET / CT and 11C-Acetate PET/CT in the restaging of prostate cancer 3.To identify specific conditions in each patient for the best selection of the radiopharmaceutical that provides more information in the restaging of prostate cancer TABLE OF CONTENTS/OUTLINE Overview of prostate cancer Properties of 18F-FDG and 11C-Acetate Indicators of prostate cancer recurrence Review of the utility of 18F FDG PET/CT and 11C-Acetate in the restaging of prostate cancer Choice of Radiopharmaceutical Example images MIE100 New Insights in Molecular Imaging of Venous Thromboembolism Education Exhibits Location: NA Participants Sina Houshmand MD : Nothing to Disclose Ali Salavati MD, MPH (Presenter): Nothing to Disclose Soren Hess : Nothing to Disclose Thomas J. Werner : Nothing to Disclose Abass Alavi MD : Nothing to Disclose TEACHING POINTS To review different molecular imaging techniques for diagnosis and assessment of venous thromboembolism (VTE). To review applications of clinical routine molecular imaging techniques for diagnosis of VTE and tumor thrombosis. TABLE OF CONTENTS/OUTLINE Venous thromboembolism (VTE) is a blood clotting disorder mostly presenting as deep vein thrombosis (DVT) and pulmonary embolism (PE) which affects up to 600,000 individuals in United States each year. Clinical symptoms of VTE are nonspecific and sometimes misleading. Additionally, side effects of available treatment plans for VTE are significant. Therefore, medical imaging plays a crucial role in proper diagnosis and avoidance from over/under diagnosis, which exposes the patient to risk. Molecular imaging techniques with different tracers have been studied for diagnosis of VTE and have shown promise in aiding the conventional structural imaging of VTE. In this exhibit we will briefly review following topics: 1. Molecular imaging methods for diagnosis of VTE i. SPECT / scintigraphy a. Ventilation-perfusion scan b. Anti D-Dimer c. GP IIb/IIIa Cyclic RGD Peptide d. Antifibrin antibodies ii. PET/CT a. FDG b. EP-2104R iii. Near Infrared fluorescence imaging MIE101 The Emerging Role of 18F-FDG and Sodium 18F Fluoride PET/CT in the Assessment of Atherosclerotic Plaques: An Update [ MI Scavenger Hunt! ] Education Exhibits Location: NA Participants Ali Salavati MD, MPH (Presenter): Nothing to Disclose Sina Houshmand MD : Nothing to Disclose Thomas J. Werner : Nothing to Disclose Benjapa Khiewvan : Nothing to Disclose Saeid Gholami MD : Nothing to Disclose Abass Alavi MD : Nothing to Disclose TEACHING POINTS To review the advances in molecular imaging of atherosclerosis and vessel wall inflammation using FDG-PET/CT and sodium 18F Fluoride -PET/CT. To review the impact of different methodological factors on vessel wall imaging and quantification of 18F-FDG and sodium 18F Fluoride PET/CT scans. TABLE OF CONTENTS/OUTLINE 18F-FDG PET/CT is a noninvasive, accurate and reproducible imaging modality that can identify and quantify inflammatory processes and prognosticate the risk for acute cardiovascular disease. Imaging vascular calcification by sodium 18F fluoride PET/CT can possibly improve cardiovascular risk stratification by detecting calcification in vascular wall and also differentiate active from indolent calcification. In this review, we will discuss advances and improvements in application of FDG-PET/CT and sodium 18F Fluoride PET/CT in atherosclerotic plaque inflammation and effects of methodological factors on accurate quantification of vessel wall inflammation. 1) FDG-PET/CT 2) Sodium 18F Fluoride 3) Methodological factors i. Delayed time point ii. Pre-scan variables iii. FDG Uptake parameters a. Qualitative b. Semi-quantitative c. Quantitative MIE102 Clinical Utility of PET-MRI in Abdominopelvic Imaging Education Exhibits Location: NA Participants Maryam Gul (Presenter): Nothing to Disclose Ammar Ahmed Chaudhry MD : Nothing to Disclose Kevin S. Baker MD : Nothing to Disclose Abbas Ahmed Chaudhry BSc : Nothing to Disclose Mubashir Sheikh : Nothing to Disclose Marlene Leslie Zawin MD : Nothing to Disclose TEACHING POINTS 1- Review physical principles and techniques of PET-MRI (positron emission tomography-magnetic resonance imaging). 2- Discuss clinical utility of using functional information obtained from a PET scan and structural information obtained from MR imaging. TABLE OF CONTENTS/OUTLINE